These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

284 related articles for article (PubMed ID: 2941889)

  • 1. [What does the micropill bring?].
    Mall-Haefeli M
    Ther Umsch; 1986 May; 43(5):365-71. PubMed ID: 2941889
    [No Abstract]   [Full Text] [Related]  

  • 2. [Effects of oral estrogen-progestin contraceptives on blood coagulation and assessment of the risk of thromboembolism].
    Surico N; Porcelli A; Petrelli P; Amedeo M; Crivello T; Ferraris G
    Minerva Ginecol; 1988 Sep; 40(9):559-62. PubMed ID: 2975773
    [No Abstract]   [Full Text] [Related]  

  • 3. What is the risk of venous thromboembolism (VTE) among women taking third-generation oral contraceptives (OCs) in comparison with those taking contraceptives containing levonorgestrel?
    Meurer LN; Slawson JG
    J Fam Pract; 2001 Feb; 50(2):108. PubMed ID: 11219554
    [No Abstract]   [Full Text] [Related]  

  • 4. Norgestimate: overview of a monophasic formulation.
    Anderson FD; Gillmer MD
    Int J Fertil Menopausal Stud; 1993; 38 Suppl 3():126-32. PubMed ID: 8260971
    [No Abstract]   [Full Text] [Related]  

  • 5. Comparative metabolic effects of oral contraceptive preparations containing different progestagens. Effects of desogestrel + ethinylestradiol on the haemostatic balance.
    Rákóczi I; Gerö G; Demeter J; Gáti I
    Arzneimittelforschung; 1985; 35(3):630-3. PubMed ID: 3158320
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Oral contraceptives and blood coagulation.
    Bonnar J; Sabra AM
    J Reprod Med; 1986 Jun; 31(6 Suppl):551-6. PubMed ID: 2941571
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Carbohydrate metabolism in women who used oral contraceptives containing levonorgestrel or desogestrel: a 6-month prospective study.
    Luyckx AS; Gaspard UJ; Romus MA; Grigorescu F; De Meyts P; Lefèbvre PJ
    Fertil Steril; 1986 May; 45(5):635-42. PubMed ID: 2938985
    [TBL] [Abstract][Full Text] [Related]  

  • 8. [Effect of the estrogen-progesterone combination preparations gravistat and Minisiston on carbohydrate metabolism].
    Albus C; Männchen E
    Zentralbl Gynakol; 1987; 109(8):521-6. PubMed ID: 3111130
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Increased levels of activated factor VII and decreased plasma protein S activity and circulating thrombomodulin during use of oral contraceptives.
    Quehenberger P; Loner U; Kapiotis S; Handler S; Schneider B; Huber J; Speiser W
    Thromb Haemost; 1996 Nov; 76(5):729-34. PubMed ID: 8950781
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Action of hormonal contraceptives on the coagulation system and some of its inhibitors.
    Misz M; Beck P
    Acta Med Hung; 1986; 43(3):301-10. PubMed ID: 2438639
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Effects of second and third generation oral contraceptives and their respective progestagens on the coagulation system in the absence or presence of the factor V Leiden mutation.
    Kemmeren JM; Algra A; Meijers JC; Bouma BN; Grobbee DE
    Thromb Haemost; 2002 Feb; 87(2):199-205. PubMed ID: 11859850
    [TBL] [Abstract][Full Text] [Related]  

  • 12. [Our experience with the use of the contraceptive preparations Femovan and Triquilar from the Schering firm].
    Milchev N; Terzhumanov R; Grozdanov G; Krumov G
    Akush Ginekol (Sofiia); 1992; 31(2):42-3. PubMed ID: 1342561
    [No Abstract]   [Full Text] [Related]  

  • 13. Development of the ratio of levonorgestrel, 0.15 mg, to ethinyl estradiol, 0.03 mg.
    Christie T
    J Reprod Med; 1983 Jan; 28(1 Suppl):63-5. PubMed ID: 6403701
    [No Abstract]   [Full Text] [Related]  

  • 14. Effects of two low-dose oral contraceptives on erythrocyte superoxide dismutase, catalase and glutathione peroxidase activities.
    Jendryczko A; Tomala J; Janosz P
    Zentralbl Gynakol; 1993; 115(11):469-72. PubMed ID: 8296490
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Effects on coagulation of levonorgestrel- and desogestrel-containing low dose oral contraceptives: a cross-over study.
    Middeldorp S; Meijers JC; van den Ende AE; van Enk A; Bouma BN; Tans G; Rosing J; Prins MH; Büller HR
    Thromb Haemost; 2000 Jul; 84(1):4-8. PubMed ID: 10928461
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Clinical experience with an ethinyl estradiol-desogestrel oral contraceptive.
    Van Trappen Y; Duvivier P; Thiery M; Van Kets H; Defoort P; Parewijck W; Derom R; Kermans G; Schoofs P
    Arzneimittelforschung; 1989 Jun; 39(6):717-9. PubMed ID: 2528355
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Third generation oral contraceptives containing desogestrel and gestodene and the risk of thrombosis.
    Griffin JP
    Adverse Drug React Toxicol Rev; 1996 Mar; 15(1):5-7. PubMed ID: 8920631
    [No Abstract]   [Full Text] [Related]  

  • 18. Risk of nonfatal venous thromboembolism with oral contraceptives containing norgestimate or desogestrel compared with oral contraceptives containing levonorgestrel.
    Jick SS; Kaye JA; Russmann S; Jick H
    Contraception; 2006 Jun; 73(6):566-70. PubMed ID: 16730485
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Cytogenetic study of blood in women who had used oral contraceptives.
    Fridrichová I
    Neoplasma; 1990; 37(5):545-53. PubMed ID: 1700312
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Atypical reserve cell hyperplasia of cervical glands, simulating adenocarcinoma. An undescribed reversible lesion in a woman taking oral contraceptives.
    Filotico M; Grasso S
    Tumori; 1981 Oct; 67(5):491-6. PubMed ID: 7324178
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 15.